Details for New Drug Application (NDA): 206081
✉ Email this page to a colleague
NDA 206081 describes SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE, which is a drug marketed by Mylan and Sun Pharm and is included in two NDAs. It is available from one supplier. Additional details are available on the SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE profile page.
The generic ingredient in SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
The generic ingredient in SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
Summary for 206081
| Tradename: | SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE |
| Applicant: | Sun Pharm |
| Ingredient: | metformin hydrochloride; saxagliptin hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 500MG;EQ 5MG BASE | ||||
| Approval Date: | Jul 31, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM;EQ 2.5MG BASE | ||||
| Approval Date: | Jul 31, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM;EQ 5MG BASE | ||||
| Approval Date: | Jul 31, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
